Responses
Immunotherapy biomarkers
Original research
Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.